跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/ISRCTN15839666
ISRCTN15839666已完成未知

se of the Skin Cancer Quality of Life Impact Tool (SCQOLIT) – a feasibility study in non­melanoma skin cancers

Oxford University Hospitals NHS Trust0 个研究点目标入组 300 人开始时间: 2016年2月3日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
未知
状态
已完成
入组人数
300
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

  1. 2016 results presented at ISOQOL in 2016: https://www.ncbi.nlm.nih.gov/pubmed/27650289 (added 29/04/2019) 2. 2017 results presented at the 97th Annual Meeting of the British Association of Dermatologists in 2017: http://www.bad.org.uk/shared/get-file.ashx?id=5779&itemtype=document (added 29/04/2019)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • •1. Aged 18 years or above
  • •2. Participant is willing and able to give informed consent for participation in the study.
  • •3. All patients with a histopathological diagnosis of NMSC (primary or recurrent disease)
  • •4. All treatments used for NMSC will be included in the study; excision, shave excision, curettage and cautery, Mohs micrographic surgery, photodynamic therapy and topical treatments e.g. imiquimod cream

排除标准

  • •1. Concurrent internal malignancy as this is likely to significantly influence quality of life (QOL)
  • •2. Patients referred on to other specialties for management of their skin cancer e.g. Plastic surgeons / Clinical oncology
  • •3. Other significant dermatological diseases e.g. severe inflammatory or blistering skin conditions as this may influence QOL
  • •4. Inability to consent for themselves

研究者

相似试验

已完成
不适用
Utility of the Skin Cancer Quality of Life Impact ToolSkin NeoplasmSquamous Cell CarcinomaBasal Cell Carcinoma
NCT02580916Oxford University Hospitals NHS Trust318
已完成
不适用
Quality of Life (QoL) Assessment in Cancer Patients and Survivors With Dermatologic Conditions Using Dermatologic QoL InstrumentsCancerDermatologic Conditions
NCT02296450Memorial Sloan Kettering Cancer Center839
招募中
不适用
Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.Kidney CancerHead Neck CancerBreast CancerGastric CancerMelanomaBladder CancerLung CancerSkin Cancer
NCT05878964Fondazione Policlinico Universitario Agostino Gemelli IRCCS420
已完成
不适用
Quality of life of the cancer patients with the target therapy induced dermatologic toxicitiesCancer
JPRN-UMIN000024377Faculty of Nursing and Medical Care, Keio University100
招募中
不适用
Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29Cutaneous Lymphoma
NCT04670874City of Hope Medical Center1,250